Oxford Cannabinoid Technologies (OCT) develops non-opioid, non-addictive pain pharmaceuticals. Its lead product OCT461201 (“201”) is an oral product to relieve peripheral nerve pain caused by cancer chemotherapy (CIPN) and irritable bowel syndrome (IBS). Management estimate that the global CIPN mar
23 May 2023
Phase 1 approval for lead chronic pain drug
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Phase 1 approval for lead chronic pain drug
Oxford Cannabinoid Technologies Holdings Plc (OCTP:LON) | 0.4 0 (-1.4%) | Mkt Cap: 3.81m
- Published:
23 May 2023 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
4
Oxford Cannabinoid Technologies (OCT) develops non-opioid, non-addictive pain pharmaceuticals. Its lead product OCT461201 (“201”) is an oral product to relieve peripheral nerve pain caused by cancer chemotherapy (CIPN) and irritable bowel syndrome (IBS). Management estimate that the global CIPN mar